Please login to the form below

Not currently logged in
Email:
Password:

saxagliptin

This page shows the latest saxagliptin news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

Among the other highlights from the CHMP meeting was the withdrawal by AstraZeneca (AZ) of an application to market diabetes combination Qtern (saxagliptin/dapagliflozin).

Latest news

  • FDA won't add outcomes data to Januvia label FDA won't add outcomes data to Januvia label

    Those concerns have caused warnings to be imposed on some rival drugs, namely AstraZeneca's Onglyza (saxagliptin) and Takeda's Nesina (alogliptin).

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... The FDA turned down Qtern with a request for more data 16 months ago,

  • 2017 set to be a 2017 set to be a "defining year" for AZ

    And two other new launches, Bevespi (glycopyrrolate and formoterol fumarate) for chronic obstructive pulmonary disease (COPD) and combination diabetes therapy Qtern (saxagliptin and dapagliflozin), will also help drive the recovery, said

  • EU clears AZ's FDA-rejected diabetes combination EU clears AZ's FDA-rejected diabetes combination

    Qtern combines the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) with SGLT2 inhibitor Farxiga/Forixiga (saxagliptin), and is the second drug of its type on the market after

  • Gilead, Merck get CHMP backing for new hep C combinations Gilead, Merck get CHMP backing for new hep C combinations

    At its meeting last week the CHMP also gave a green light to AstraZeneca's DPP-4 inhibitor/SGLT2 inhibitor combination Qtern (saxagliptin/dapagliflozin) as a treatment for type 2 diabetes.

More from news
Approximately 6 fully matching, plus 50 partially matching documents found.

Latest Intelligence

  • Interview: Christopher Boulton, AstraZeneca Interview: Christopher Boulton, AstraZeneca

    Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics